Phathom Pharmaceuticals Inc (PHAT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Phathom Pharmaceuticals Inc (PHAT) has a cash flow conversion efficiency ratio of 0.033x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.12 Million) by net assets ($-422.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See PHAT equity to assets ratio to measure how much of total assets are equity-financed.
Phathom Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Phathom Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Phathom Pharmaceuticals Inc (PHAT) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Phathom Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Phathom Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GuangDong Rifeng Electric Cable Co Ltd
SHE:002953
|
0.021x |
|
PNC Infratech Limited
NSE:PNCINFRA
|
0.633x |
|
Hubeiyichang Transportation Group Co Ltd
SHE:002627
|
0.023x |
|
Jiangsu Baichuan HighTech New Materials Co Ltd
SHE:002455
|
0.044x |
|
Beijing Bayi Space LCD Technology Co Ltd
SHG:688181
|
0.057x |
|
indie Semiconductor Inc
NASDAQ:INDI
|
-0.041x |
|
Velocity Financial Llc
NYSE:VEL
|
0.018x |
|
Prima Marine Public Company Limited
BK:PRM
|
0.094x |
Annual Cash Flow Conversion Efficiency for Phathom Pharmaceuticals Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Phathom Pharmaceuticals Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see PHAT stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-253.58 Million | $-266.77 Million | 1.052x | -44.36% |
| 2023-12-31 | $-72.76 Million | $-137.58 Million | 1.891x | -3.46% |
| 2022-12-31 | $-74.81 Million | $-146.53 Million | 1.959x | +195.20% |
| 2021-12-31 | $72.16 Million | $-148.46 Million | -2.057x | -473.56% |
| 2020-12-31 | $194.27 Million | $-69.69 Million | -0.359x | -123.97% |
| 2019-12-31 | $227.96 Million | $-36.51 Million | -0.160x | -120.13% |
| 2018-12-31 | $-1.29 Million | $-1.02 Million | 0.795x | -- |
About Phathom Pharmaceuticals Inc
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical t… Read more